SCHAUMBURG, Ill., Oct. 5 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, today announced that it has launched ampicillin and sulbactam for injection, USP and ampicillin for injection, USP. The ampicillin and sulbactam product will be sold in 1.5 g and 3g single-dose and 15 g pharmacy bulk package vials. The ampicillin product will be sold in five presentations: 250 mg, 500 mg, 1 g, and 2 g single-dose vials and 10 g pharmacy bulk package vials.
Full year (July 2009 June 2010) sales of ampicillin and sulbactam for injection in the United States were approximately $40 million and approximately $42 million for ampicillin for injection, as estimated by IMS.
“The launch of these products increases Sagent’s anti-infectives portfolio to eleven injectable products in a variety of sizes, concentrations and packaging configurations,” said Jeffrey M. Yordon, chief executive officer, founder, and chairman of the board of Sagent. “As we continue to expand our product offering, we are able to provide customers with a growing array of anti-infectives, each featuring our proprietary PreventIV Measures labeling and packaging.”
About Ampicillinand Sulbactam for Injection, USP
Ampicillin and sulbactam consists of the semi-synthetic antibiotic ampicillin and the beta-lactamase inhibitor sulbactam sodium. The product is indicated for the treatment of infections such as skin and skin structure infections, intra-abdominal infections and gynecological infections caused by susceptible strains of designated microorganisms.
About Ampicillin for Injection, USP
Ampicillin for injection is a beta-lactam antibiotic indicated in the treatment of infections including respiratory tract infections, bacterial meningitis, septicemia and endocarditis, urinary tract infections, and certain gastrointestinal infections caused by susceptible strains of designated microorganisms.
The package inserts for all products are available at www.SagentPharma.com and contain detailed information about the indication, warnings, complete side effect profile and prescribing information.
About PreventIV Measures
PreventIV Measures is a comprehensive, user-driven and patient-centered approach to product labeling and packaging that is designed to help prevent medication errors. It incorporates unique label and carton designs, cap and label colors, bar coding and other features that are designed to make it easier to differentiate drugs and identify the correct dose.
About Sagent Pharmaceuticals, Inc.
Sagent Pharmaceuticals, founded in 2006, is a privately held specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products. Sagent has created a unique, global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, quickly yielding an extensive portfolio of pharmaceutical products that fulfills the evolving needs of patients.
To Discover Injectables Excellence and learn more about Sagent, please visit www.SagentPharma.com.
SOURCE Sagent Pharmaceuticals, Inc.
